PLSE

Pulse Biosciences, Inc. (PLSE) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Pulse Biosciences is a development-stage medical device company focused on its proprietary Nano-pulse Stimulation (NPS) technology. The company has shifted its primary focus from dermatology to cardiology (specifically atrial fibrillation) and soft tissue ablation. It currently generates no revenue and relies on equity financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the six months ended June 30, 2025, increased by $14.4 million compared to the same period in 2024, driven primarily by higher operating expenses.
• R&D and G&A Growth: Research and Development expenses rose by $8.4 million YTD, and General and Administrative expenses increased by $7.5 million YTD. These increases were largely attributed to higher stock-based compensation, increased compensation costs, and external research fees.
• Stock-Based Compensation Spike: Stock-based compensation expense more than doubled YTD compared to 2024 ($10.9 million vs. $3.8 million), reflecting new executive grants with market and performance-based vesting conditions.
• Financing Activity: The company received $14.1 million in gross proceeds from the exercise of warrants related to the 2024 Rights Offering during the first six months of 2025.

Outlook, Management Commentary, and Risks

• Product Pipeline:
  • Soft Tissue: Received FDA 510(k) clearance for the nsPFA Percutaneous Electrode System. Pilot commercialization is underway with over 140 patient procedures completed at nine U.S. sites. A clinical trial to support full commercialization is expected to commence in Q3 2025.
  • Cardiology: Received FDA Breakthrough Device Designation for the nsPFA Cardiac Surgery System. An Investigational Device Exemption (IDE) has been submitted for a pivotal trial. Clinical studies for the nsPFA 360° Cardiac Catheter are ongoing in Europe with promising data; a U.S. IDE pivotal study is expected to commence soon.
• Liquidity: Management believes existing cash of $106.3 million is sufficient to fund operations for at least the next 12 months. However, the company explicitly states it will need to raise additional capital in the future to fully fund its business plan.
• Key Risks:
  • Capital Needs: Failure to secure additional financing could force the company to delay clinical trials, reduce headcount, or cease operations.
  • Regulatory Uncertainty: No assurance that product candidates will obtain FDA approval or that clinical results will be favorable.
  • Concentration of Ownership: Co-Chairman Robert W. Duggan owns approximately 72% of the outstanding common stock, limiting minority shareholder influence.
  • Performance Vesting: Management determined it is not probable that performance conditions for certain new executive stock options will be achieved; thus, no expense was recognized for these specific awards in Q2 2025.

Investor Verification Checklist

• Verify the timeline and enrollment status of the upcoming U.S. pivotal clinical trials for the Cardiac Clamp and Catheter.
• Monitor the progress of the pilot commercialization for the Percutaneous Electrode System and any revenue recognition from these early sales.
• Assess the company's cash burn rate relative to the $106.3 million cash balance to determine the runway for future financing needs.
• Review the terms of the 2024 Rights Offering warrants, specifically the redemption features tied to stock price thresholds ($16.50 and $22.00).
• Confirm the status of the "One Big Beautiful Bill Act" (OBBBA) impact on the company's tax position as noted in subsequent events.